Category: Uncategorized

  • Pridopidine

    Plain-language summaryIntrigue 62 / 100

    Pridopidine started life as a dopamine stabilizer for Huntington disease and was later reclassified as a high-affinity sigma-1 agonist when its true binding profile was characterized. Originally developed at NeuroSearch and now at Prilenia Therapeutics, it failed the phase 3 PRIDE-HD trial in Huntington but has continued in ALS development based on encouraging phase 2 signals in that population. The reclassification story is interesting because it changed how investigators think about both pridopidine and the sigma-1 target itself. Whether the current ALS program produces meaningful efficacy remains an open question. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Selective sigma-1 receptor agonist with low-affinity dopamine D2 receptor antagonism and CYP2D6 auto-inhibition

    A 4-phenylpiperidine sigma-1 receptor agonist originally developed as a dopaminergic stabilizer, repositioned on the basis of high-affinity sigma-1 binding and neuroprotective activity in Huntington disease and amyotrophic lateral sclerosis models, with Phase 3 clinical data in Huntington disease and an FDA-cleared Phase 3 program in ALS.

    Abstract

    Pridopidine (ACR16; 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine; CAS 346688-38-8; molecular formula C15H23NO2S; molecular weight 281.41) is a selective sigma-1 receptor (S1R) agonist with a binding affinity (Ki) of approximately 57 nM at the human sigma-1 receptor and substantially lower affinity at the dopamine D2 receptor (Ki approximately 2950 nM), the dopamine D3 receptor (Ki approximately 1630 nM), the adrenergic alpha-2C receptor (Ki approximately 1580 nM), and the sigma-2 receptor (Ki approximately 5450 nM). The compound was synthesized at A. Carlsson Research (later NeuroSearch) as part of a structure-activity exploration of 4-phenylpiperidine dopamine D2 receptor ligands with fast dissociation kinetics and was originally classified as a “dopaminergic stabilizer” on the basis of its state-dependent modulation of dopaminergic tone in behavioral models. Subsequent binding, functional, and positron emission tomography studies established that the principal pharmacological target at clinically relevant concentrations is the sigma-1 receptor, an endoplasmic reticulum chaperone protein located at the mitochondria-associated membrane that regulates calcium homeostasis, mitochondrial function, brain-derived neurotrophic factor (BDNF) trafficking and secretion, endoplasmic reticulum stress responses, autophagy, and synaptic plasticity. Pridopidine has demonstrated neuroprotective and neurorestorative activity in preclinical models of Huntington disease (YAC128 transgenic mice, R6/2 mice), amyotrophic lateral sclerosis (SOD1G93A mice), Parkinson disease (6-OHDA lesioned mice), and glaucoma (optic nerve crush and microbead occlusion models), with effects dependent on sigma-1 receptor activation and abolished in sigma-1 receptor knockout animals.

    Clinical development has focused primarily on Huntington disease. Four randomized controlled trials (Lundin 2010, MermaiHD, HART, PRIDE-HD) evaluated pridopidine at doses of 20 to 112.5 mg per day in a combined population of over 1,100 patients. The Phase 3 MermaiHD trial (437 patients, 26 weeks) did not meet its primary motor endpoint (modified Motor Score) but demonstrated nominally significant improvement on the total Unified Huntington’s Disease Rating Scale (UHDRS) Total Motor Score. The Phase 2 PRIDE-HD trial (408 patients, 52 weeks) reported that pridopidine 45 mg twice daily was associated with maintenance of Total Functional Capacity (TFC) compared to placebo at 52 weeks, a finding extended to five years in the Open-HART open-label extension. The Phase 3 PROOF-HD trial (499 patients, 65 weeks) did not meet its primary endpoint (TFC change) in the overall population but demonstrated statistically significant benefit on TFC, composite UHDRS score, and multiple secondary endpoints in the pre-specified subgroup of participants not receiving antidopaminergic medications. A European Marketing Authorisation Application was submitted in 2024 for the treatment of adults with Huntington disease; the Committee for Medicinal Products for Human Use recommended refusal in July 2025, and Prilenia Therapeutics has announced plans for a confirmatory global Phase 3 study.

    In amyotrophic lateral sclerosis, pridopidine was evaluated in the Phase 2 HEALEY ALS Platform Trial (121 participants, 24 weeks). The primary endpoint (ALSFRS-R total score change) was not met in the full analysis set, but subgroup analyses in patients with early and rapidly progressive disease demonstrated a 32 percent slowing of ALSFRS-R decline, a 62 percent slowing of respiratory decline, and a prolongation of median survival from approximately 300 to 600 days. The United States Food and Drug Administration cleared a pivotal Phase 3 trial (PREVAiLS, 500 patients) in December 2025, with recruitment planned for early 2026.

    Pharmacokinetics are characterized by oral absorption, hepatic CYP2D6-mediated N-depropylation, and a single-dose elimination half-life of approximately 6 hours in extensive CYP2D6 metabolizers and 15 hours in poor metabolizers. Pridopidine is a metabolism-dependent inhibitor of CYP2D6, producing auto-inhibition that extends the effective half-life to 10 to 14 hours regardless of CYP2D6 genotype on repeated dosing, an unusual pharmacokinetic property that reduces inter-individual variability at steady state and eliminates the requirement for CYP2D6 genotype-based dose adjustment. The compound is well tolerated at doses up to 112.5 mg per day; the most common adverse events are insomnia, diarrhea, nausea, and dizziness, with no clinically significant differences from placebo in serious adverse event rates across pooled trial data. QTc prolongation at the 45 mg twice daily dose is not considered clinically relevant.

    This monograph reviews the chemistry and synthesis of pridopidine; the sigma-1 receptor mechanism in molecular and cellular detail; the comprehensive pharmacokinetic record including CYP2D6 auto-inhibition; the preclinical neuroprotective evidence across multiple disease models; the clinical evidence base across Huntington disease, amyotrophic lateral sclerosis, and exploratory indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five sigma-1 receptor candidates against pridopidine on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority as of the monograph revision date. It is available as a research-grade preparation from multiple chemical suppliers; investigators should obtain analytical confirmation of identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1463Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • 7,8-Dihydroxyflavone

    Naturally occurring flavone and selective small-molecule tropomyosin receptor kinase B (TrkB) agonist with BDNF-mimetic neurotrophic activity

    A naturally occurring dihydroxylated flavone identified through cell-based TrkB receptor screening as the first orally bioactive small-molecule brain-derived neurotrophic factor mimetic, distinguished by selective TrkB agonism, blood-brain barrier penetration, and broad preclinical neuroprotective and procognitive efficacy across neurodegenerative, neuropsychiatric, and metabolic disease models.

    Abstract

    7,8-Dihydroxyflavone (7,8-DHF), also designated tropoflavin, is a naturally occurring flavone first isolated from the leaves of Godmania aesculifolia and subsequently identified in Tridax procumbens, Primula vulgaris, and other plant species. The compound was characterized in 2010 by Jang et al. at Emory University as the first orally bioactive, blood-brain-barrier-penetrant small-molecule agonist of the tropomyosin receptor kinase B (TrkB), the principal high-affinity signaling receptor for brain-derived neurotrophic factor (BDNF) [1]. 7,8-DHF binds the extracellular domain of TrkB with a dissociation constant of approximately 320 nM by filter binding assay and approximately 15.4 nM by surface plasmon resonance, triggering receptor dimerization, autophosphorylation at tyrosine residues 706/707, and activation of the downstream PI3K/Akt and MAPK/ERK signaling cascades that mediate neuronal survival, synaptic plasticity, and long-term potentiation [1, 2]. The compound displays selectivity for TrkB over the related neurotrophin receptors TrkA and TrkC and does not activate TrkB kinase-dead mutants, confirming that the phosphorylation signal arises from the receptor itself rather than from off-target tyrosine kinases [2].

    Pharmacokinetic characterization in rodents reveals oral bioavailability of approximately 4.6 percent, a plasma half-life of approximately 134 minutes, rapid brain penetration with peak brain concentrations at 10 minutes after oral dosing, and primary hepatic metabolism through glucuronidation, sulfation, and catechol-O-methyltransferase-mediated methylation [3, 4]. The O-methylated metabolites (7-methoxy-8-hydroxyflavone and 7-hydroxy-8-methoxyflavone) retain TrkB agonist activity in vitro and in vivo, extending the effective pharmacodynamic window beyond the parent compound [5]. The modest oral bioavailability prompted the development of the prodrug R13 (a carbamate ester derivative) by the Ye laboratory, which increases oral bioavailability to approximately 10.5 percent and extends the plasma half-life to approximately 220 minutes [6]. R13 has entered Phase 1 clinical evaluation for Alzheimer’s disease, representing the most advanced clinical translation of TrkB agonist pharmacology from this scaffold.

    Preclinical pharmacology is extensive. In Alzheimer’s disease models, 7,8-DHF reduces BACE1 elevation, decreases amyloid-beta deposition, restores hippocampal synaptic density, and rescues spatial and working memory deficits in 5XFAD, APP/PS1, and Tg2576 transgenic mice at oral doses of 5 mg/kg/day [7, 8, 9]. In Parkinson’s disease models, the compound protects dopaminergic neurons from MPTP- and rotenone-induced degeneration and improves motor function [10]. In depression models, 7,8-DHF reverses learned helplessness, chronic mild stress, and social defeat stress phenotypes through restoration of hippocampal and prefrontal cortical TrkB-BDNF signaling [11, 12]. Additional preclinical efficacy has been demonstrated in models of Huntington’s disease, amyotrophic lateral sclerosis, traumatic brain injury, post-traumatic stress disorder, Rett syndrome, fragile X syndrome, retinal ganglion cell degeneration, and diet-induced obesity [13, 14, 15, 16, 17, 18, 19].

    Safety characterization in chronic rodent studies at 5 mg/kg/day for periods up to 6 months has revealed no pathological changes in major organs, no hematological abnormalities, and no observable toxicity at doses producing robust TrkB activation [2]. A 7-month oral dosing study in a non-human primate model of Parkinson’s disease similarly reported no toxic reactions [20]. No human clinical trial data for the parent compound 7,8-DHF have been published; clinical development has proceeded through the prodrug R13. This monograph reviews the chemistry, natural sources, and structure-activity relationships of 7,8-DHF; the TrkB receptor pharmacology in molecular and cellular detail; the pharmacokinetic profile including metabolism and prodrug development; the preclinical evidence base across neurodegenerative, neuropsychiatric, and metabolic indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety characterization; and a comparative assessment of five TrkB-targeted candidates against 7,8-DHF on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1488Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • P7C3-A20

    Aminopropyl carbazole neuroprotective agent functioning as a nicotinamide phosphoribosyltransferase (NAMPT) positive allosteric modulator

    A synthetic 3,6-dibromocarbazole derivative discovered through target-agnostic in vivo neurogenesis screening, distinguished by its activation of the NAD+ salvage enzyme NAMPT and broad neuroprotective efficacy across preclinical models of traumatic brain injury, ischemic stroke, Parkinson disease, amyotrophic lateral sclerosis, and Alzheimer disease.

    Abstract

    P7C3-A20, the fluorinated and methoxylated analog of the parent aminopropyl carbazole P7C3, is a synthetic neuroprotective compound identified through iterative structure-activity optimization of a chemical series originally discovered in a target-agnostic in vivo screen for enhancers of adult hippocampal neurogenesis conducted by Pieper, McKnight, and colleagues at the University of Texas Southwestern Medical Center [1]. The parent compound P7C3 was one of eight hits from a library of approximately 1,000 small molecules screened for their ability to augment the survival of newborn neurons in the subgranular zone of the murine dentate gyrus. Subsequent medicinal chemistry optimization, principally the replacement of the central hydroxyl with fluorine and the introduction of a methoxy substituent on the aniline ring, yielded P7C3-A20, which demonstrated approximately ten-fold greater proneurogenic potency than the parent compound while retaining favorable oral bioavailability, blood-brain barrier penetration, and tolerability in chronic dosing studies in rodents and nonhuman primates [2, 3]. The molecular target of P7C3-A20 was identified by Wang et al. (2014) as nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway [4]. P7C3-A20 functions as a positive allosteric modulator of NAMPT, enhancing the conversion of nicotinamide to nicotinamide mononucleotide (NMN) and thereby augmenting intracellular NAD+ levels under conditions of metabolic stress without elevating NAD+ to supraphysiologic concentrations. This mechanism distinguishes P7C3-A20 from direct NAD+ precursor supplementation strategies (nicotinamide riboside, nicotinamide mononucleotide) by preserving endogenous feedback regulation of the salvage pathway. The downstream consequences of NAMPT activation and NAD+ restoration include maintenance of sirtuin deacetylase activity (particularly SIRT1 and SIRT3), protection of mitochondrial bioenergetics, suppression of oxidative stress and DNA damage, attenuation of neuroinflammation through microglial modulation, and enhancement of the survival of newly generated neurons during adult hippocampal neurogenesis. The preclinical pharmacology of P7C3-A20 has been characterized across an unusually broad spectrum of neurodegenerative and neurotraumatic disease models. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson disease, P7C3-A20 substantially preserved dopaminergic neurons in the substantia nigra [5]. In the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS), P7C3-A20 reduced motor neuron cell death in the spinal cord [6]. In models of traumatic brain injury (TBI), P7C3-A20 blocked axonal degeneration and preserved neurological function when administered acutely [7], and, in a landmark 2020 study, restored blood-brain barrier integrity, arrested chronic neurodegeneration, and recovered normal cognitive function when treatment was initiated a full twelve months after the initial injury [8]. In rat models of focal ischemic stroke, P7C3-A20 promoted post-ischemic neurogenesis, restored cortical NAD+ levels, and improved chronic sensorimotor and cognitive outcomes [9]. In retinal degeneration models, the P7C3 class protected retinal ganglion cells from optic nerve injury [10]. In 2025, Vazquez-Rosa et al. published a study in Cell Reports Medicine demonstrating that P7C3-A20 treatment of 5xFAD and PS19 transgenic mice with advanced Alzheimer-like pathology produced comprehensive reversal of tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, and neuroinflammation, with full cognitive recovery and normalization of the clinical biomarker p-tau217 [11]. P7C3-A20 has not entered human clinical trials as of the most recent monograph revision. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers at high purity. This monograph reviews the chemistry, synthesis, and structure-activity relationships of P7C3-A20; the NAMPT-mediated mechanism of action; the preclinical pharmacokinetic profile; the extensive preclinical pharmacology across neurodegenerative and neurotraumatic models; the current clinical development status; sourcing and quality considerations; reconstitution and handling; stack interactions; the adverse-event and safety profile from preclinical studies; and a comparative assessment of five neuroprotective or NAD-augmenting compounds against P7C3-A20 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1491Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • PRE-084

    Selective sigma-1 receptor agonist derived from phencyclidine with neuroprotective, nootropic, and neurotrophic activity

    A phencyclidine-derived sigma-1 receptor agonist developed as a pharmacological tool compound, distinguished by high selectivity over sigma-2 and PCP receptors and by a broad preclinical literature spanning neuroprotection in motor neuron disease, stroke, Parkinson’s disease, cognitive impairment, and antidepressant activity.

    Abstract

    PRE-084 (2-(4-morpholino)ethyl 1-phenylcyclohexane-1-carboxylate) is a selective agonist of the sigma-1 receptor (sigma-1R) originally identified in 1991 by Su and colleagues at the National Institute on Drug Abuse through a systematic structure-activity program that sought to separate sigma receptor affinity from phencyclidine (PCP) receptor binding in the parent cyclohexylamine scaffold [1]. The compound binds the sigma-1 receptor with an IC50 of approximately 44 nM in radioligand displacement assays and exhibits selectivity ratios exceeding 2000-fold over the PCP binding site (IC50 greater than 100,000 nM) and approximately 300-fold over the sigma-2 receptor subtype (IC50 approximately 13,091 nM), establishing it as one of the most widely used pharmacological tools for interrogating sigma-1 receptor function in vitro and in vivo [1, 2]. The sigma-1 receptor itself is a ligand-regulated chaperone protein resident at the mitochondria-associated endoplasmic reticulum membrane (MAM), where it modulates calcium signaling through interactions with inositol 1,4,5-trisphosphate receptors, regulates protein folding and endoplasmic reticulum stress responses, and participates in diverse signal transduction cascades including the NF-kappaB, ERK/CREB, and protein kinase C pathways [3, 4]. PRE-084 has not been advanced to human clinical trials and carries no regulatory approval in any jurisdiction; its utility is exclusively as a research-grade pharmacological probe. The preclinical literature on PRE-084 is nonetheless substantial and spans multiple therapeutic domains. In amyotrophic lateral sclerosis, daily administration of PRE-084 to SOD1-G93A transgenic mice from eight weeks of age preserved spinal motoneuron survival, maintained compound muscle action potential amplitudes, improved locomotion, and extended overall survival, with neuroprotective effects attributed to protein kinase C-mediated phosphorylation of the NMDA receptor NR1 subunit and reduction of microglial reactivity [5, 6]. Comparable neuroprotection was demonstrated in the wobbler mouse model of motor neuron disease not linked to SOD1 mutation, broadening the mechanistic generalizability [7]. In ischemic stroke models, PRE-084 at 5 mg/kg intraperitoneally reduced infarct volume and neurological deficit scores after embolic middle cerebral artery occlusion in rats, with the mechanism involving suppression of pro-inflammatory cytokines (interleukin-1 beta, tumor necrosis factor alpha) and enhancement of anti-inflammatory cytokines [8]. In Parkinson’s disease models, PRE-084 administration normalized motor dysfunction and prevented dopaminergic neuron loss in both 6-hydroxydopamine and MPTP paradigms through sigma-1 receptor-mediated promotion of PINK1/Parkin mitophagy and enhancement of dopamine transporter expression [9, 10]. Cognitive and nootropic effects have been characterized across multiple paradigms: PRE-084 attenuated MK-801-induced amnesia, amyloid-beta peptide-induced learning impairment, and spatial learning deficits in aged rats, with mechanisms involving upregulation of NMDA receptor expression in the hippocampus and activation of the ERK/CREB/BDNF signaling axis [11, 12, 13]. Antidepressant-like activity has been demonstrated in the forced swim test in multiple mouse strains at doses of 30 to 60 mg/kg, with enhanced efficacy in amyloid-beta-treated animals [14, 15]. Additional preclinical applications include cardioprotection in myocardial ischemia-reperfusion injury, neuroprotection in perinatal excitotoxic brain injury, glial modulation in spinal muscular atrophy, protection against Huntington’s disease-associated cellular degeneration through NF-kappaB-mediated calpastatin upregulation, and attenuation of sepsis-associated encephalopathy [16, 17, 18, 19, 20]. Pharmacokinetic characterization in mice after intraperitoneal administration at 10 mg/kg reveals rapid central nervous system penetration (brain concentration 773.6 ng/g at five minutes), a plasma elimination half-life of approximately 195 minutes, and stability in biological matrices for at least 24 hours [2]. The compound is supplied as the hydrochloride salt by multiple research chemical vendors at greater than 98 percent purity and is reconstituted in aqueous solution or dimethyl sulfoxide for experimental use. This monograph reviews the chemistry, synthesis, and selectivity of PRE-084; the sigma-1 receptor chaperone pharmacology in molecular detail; the pharmacokinetic profile; the full preclinical evidence base across neurodegenerative, cerebrovascular, cognitive, affective, and cardioprotective domains; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse event and safety signal from preclinical data; and a comparative assessment of five sigma-1 receptor candidates (SA4503/cutamesine, ANAVEX2-73/blarcamesine, pridopidine, igmesine, and fluvoxamine) against PRE-084 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1464Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • 17-alpha-Estradiol

    Plain-language summaryIntrigue 75 / 100

    17-alpha-Estradiol is the mirror-image isomer of regular estradiol, identical except for the orientation of one hydroxyl group. That single difference makes it bind classical estrogen receptors about 100 times more weakly, eliminating most of the feminizing effects. The reason it appears in longevity literature: the NIA Interventions Testing Program (a multi-laboratory rodent screening program designed to spot real lifespan-extending drugs) reproducibly showed that 17-alpha-estradiol extends male mouse lifespan by about 12 percent, with no effect in females. The mechanism is incompletely understood, possibly involving non-classical estrogen receptors or hypothalamic effects. One of a handful of compounds with replicated ITP data, but no human trials. Genuinely intriguing sleeper. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Non-feminizing endogenous estradiol stereoisomer with 5-alpha-reductase inhibitory activity and lifespan-extending properties

    A naturally occurring 17-alpha-epimer of estradiol with approximately 100-fold reduced classical estrogen receptor affinity, topical registration as alfatradiol for androgenetic alopecia, and reproducible male-specific lifespan extension in the NIA Interventions Testing Program, mediated through estrogen receptor alpha signaling in the hypothalamus and liver.

    Abstract

    17-alpha-Estradiol (estra-1,3,5(10)-triene-3,17-alpha-diol; CAS 57-91-0; alfatradiol; molecular formula C18H24O2; molecular weight 272.39 g/mol) is the 17-alpha-stereoisomer of the principal mammalian estrogen 17-beta-estradiol, distinguished solely by the axial (alpha) orientation of the hydroxyl group at carbon 17 of the steroid D-ring. The compound occurs endogenously at low concentrations in mammalian brain and peripheral tissues and has been characterized since the 1950s as a weak estrogen with approximately 100-fold lower binding affinity for the classical nuclear estrogen receptors ER-alpha and ER-beta relative to the 17-beta-epimer [1, 2]. Despite this reduced receptor engagement, 17-alpha-estradiol retains potent estrogen receptor-independent antioxidant activity equivalent to 17-beta-estradiol in lipid peroxidation assays and neuroprotection models [3, 4], inhibits 5-alpha-reductase and aromatase in skin and hair follicle tissue (the basis for its topical registration as alfatradiol in several European jurisdictions for androgenetic alopecia) [5, 6], and has emerged as one of the most robustly validated lifespan-extending compounds in the National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse longevity screening platform.

    The ITP demonstrated that dietary 17-alpha-estradiol at 14.4 parts per million (approximately 2 mg/kg/day mouse-equivalent) extended median lifespan by approximately 19 percent in male UM-HET3 mice when initiated at 16 months of age and by approximately 11 percent when initiated at 20 months, with no lifespan extension observed in female mice at any initiation age [7, 8, 9]. The male specificity of the lifespan effect has been replicated across three independent ITP sites (the Jackson Laboratory, the University of Michigan, and the University of Texas Health Science Center) and is among the largest and most reproducible lifespan extensions reported in the ITP, comparable in magnitude to acarbose and exceeded only by rapamycin. The sex-specific pattern has driven substantial mechanistic investigation. Stout et al. (2017) demonstrated that 17-alpha-estradiol alleviates age-related metabolic and inflammatory dysfunction in male mice without inducing feminization, with treated males showing reduced fasting glucose, reduced fasting insulin, reduced glycosylated hemoglobin, reduced visceral adiposity, reduced circulating and adipose tissue pro-inflammatory cytokines, and increased AMP-activated protein kinase activity in visceral adipose tissue [10]. Steyn et al. (2018) established that 17-alpha-estradiol acts through hypothalamic pro-opiomelanocortin (POMC) expressing neurons to reduce feeding behavior, with near-complete loss of the anorectic response in POMC-neuron-ablated mice [11]. Mann et al. (2020) demonstrated through liver-specific and global ER-alpha knockout models that the metabolic health benefits of 17-alpha-estradiol (reductions in fasting insulin, HbA1c, glucose intolerance, and visceral adiposity) are mediated through estrogen receptor alpha, resolving prior uncertainty about whether a non-classical receptor was responsible [12]. Garratt et al. (2017, 2018) reported that males, but not females, metabolize 17-alpha-estradiol into one or more estriol derivatives, and that the sex-specific beneficial effects may depend on a downstream metabolite rather than on the parent compound [13, 14].

    The compound has limited human clinical data. A Phase I safety study in eight healthy postmenopausal women demonstrated tolerability of single rising oral doses (50, 100, and 200 micrograms) with no adverse events, no detectable conversion to 17-beta-estradiol, and no feminizing effects [15]. Topical formulations (alfatradiol 0.025 percent solution, marketed as Ell-Cranell alpha) are registered in Germany, Austria, and several other European jurisdictions for androgenetic alopecia in men and women, with demonstrated stabilization of hair loss through local 5-alpha-reductase inhibition and aromatase induction [5, 6]. No clinical trials of oral 17-alpha-estradiol for longevity, metabolic, or neuroprotective endpoints have been completed or registered in humans as of the monograph revision date.

    This monograph reviews the chemistry, stereochemistry, and synthesis of 17-alpha-estradiol; the molecular pharmacology across classical estrogen receptors, non-classical signaling pathways, 5-alpha-reductase inhibition, and antioxidant mechanisms; pharmacokinetics in rodent and limited human contexts; the preclinical evidence base from the ITP and mechanistic studies; the clinical evidence from the Phase I oral safety study and topical alopecia registration; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five alternative longevity or non-feminizing estrogen candidates against 17-alpha-estradiol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1475Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Palmitoylethanolamide

    Plain-language summaryIntrigue 64 / 100

    Palmitoylethanolamide (PEA) is a fatty acid amide your body makes from membrane lipids, first identified in egg yolk in 1957 because of its anti-inflammatory effects. It does not bind cannabinoid receptors directly. Instead it activates the PPAR-alpha nuclear receptor, stabilizes mast cells (the immune cells that release histamine), and competes with anandamide for the FAAH enzyme, indirectly raising endocannabinoid tone. Decades of European clinical work, particularly in Italy, support its use for chronic pain, neuropathy, and sciatica, with a generally clean safety record and meaningful effect sizes. It is sold as a supplement in the US and as a registered medical food in parts of Europe. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Endogenous N-acylethanolamide lipid mediator with peroxisome proliferator-activated receptor alpha agonism and mast cell modulatory activity

    An endogenous fatty acid amide biosynthesized from membrane phospholipids, identified as an anti-inflammatory factor in the 1950s and subsequently characterized as a peroxisome proliferator-activated receptor alpha agonist with broad analgesic, anti-inflammatory, neuroprotective, and mast cell stabilizing activity across chronic pain, neuroinflammation, and neurodegenerative disease models.

    Abstract

    Palmitoylethanolamide (PEA; CAS 544-31-0; molecular formula C18H37NO2; molecular weight 299.49 g/mol) is an endogenous fatty acid amide of the N-acylethanolamide class, biosynthesized on demand from membrane N-palmitoyl-phosphatidylethanolamine by the enzyme N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) and degraded principally by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA) to palmitic acid and ethanolamine. The compound was first identified as a crystalline anti-inflammatory factor isolated from soybean lecithin by Kuehl et al. in 1957, following earlier observations by Coburn et al. (1954) that egg yolk protected against experimental anaphylactic arthritis. The Nobel laureate Rita Levi-Montalcini and colleagues subsequently characterized PEA as a modulator of mast cell degranulation and proposed the autacoid local injury antagonism (ALIA) mechanism in 1993, establishing the conceptual framework for PEA as an endogenous resolution factor in inflammation.

    The principal molecular target of PEA is the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha), at which PEA acts as a direct agonist with an EC50 of approximately 3.1 micromolar in cell-based reporter assays. Lo Verme et al. (2005) demonstrated that the anti-inflammatory actions of PEA in carrageenan-induced paw edema and phorbol ester-induced ear edema models are abolished in PPAR-alpha knockout mice, establishing PPAR-alpha as the principal mediator of PEA anti-inflammatory pharmacology. Additional receptor targets include the orphan G-protein coupled receptors GPR55 and GPR119, the transient receptor potential vanilloid type 1 channel (TRPV1, via indirect potentiation), and a mast cell surface receptor pharmacologically consistent with a peripheral cannabinoid site. PEA does not bind with meaningful affinity to classical cannabinoid receptors CB1 or CB2 but modulates the endocannabinoid system indirectly through an entourage mechanism: competition for FAAH-mediated degradation elevates tissue levels of the endocannabinoid anandamide, thereby potentiating anandamide signaling at CB1, CB2, and TRPV1.

    The clinical evidence base for PEA spans chronic pain, neuropathic pain, neuroinflammation, and neurodegenerative disease. A 2023 systematic review and meta-analysis of double-blind randomized controlled trials (Scuteri et al., Nutrients, 2023) encompassing 12 studies and approximately 1300 patients demonstrated that oral PEA at 300 to 1200 mg daily produces statistically significant and clinically meaningful pain intensity reduction compared to placebo or active control, with effect emerging at 30 days and increasing through 60 days of treatment. Specific indications with positive randomized controlled trial evidence include sciatic pain, diabetic peripheral neuropathy, carpal tunnel syndrome, temporomandibular joint disorder, chronic low back pain, endometriosis-associated pelvic pain, and fibromyalgia. Micronized (mPEA) and ultramicronized (umPEA) particle-size formulations have been developed to overcome the poor aqueous solubility and limited oral bioavailability of native crystalline PEA, with the micronization process increasing the specific surface area and producing substantially improved absorption and tissue distribution.

    PEA exhibits a favorable safety profile consistent with its status as an endogenous compound and a natural component of the human diet (present in egg yolk, soybean lecithin, peanut meal, and other food sources). Across more than 40 clinical studies and approximately 3000 patient-exposures, no serious adverse drug reactions have been attributed to PEA supplementation at doses up to 1200 mg daily for up to 120 days. The compound is marketed as a medical food or dietary supplement in multiple European jurisdictions (Normast, PeaPure, Levagen) and is available as a research-grade preparation from multiple chemical suppliers. PEA is not approved as a drug by the United States Food and Drug Administration or by the European Medicines Agency; its regulatory status varies by jurisdiction between dietary supplement, medical food, and food for special medical purposes.

    This monograph documents the chemistry, biosynthesis, and degradation of PEA; the multi-target molecular pharmacology including PPAR-alpha agonism, GPR55 and GPR119 signaling, mast cell modulation, and entourage potentiation of endocannabinoid tone; the pharmacokinetic profile with emphasis on formulation-dependent bioavailability; the preclinical pharmacology across pain, inflammation, and neurodegeneration models; the clinical evidence base in chronic and neuropathic pain, neuroinflammatory conditions, and neurodegenerative disease; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative anti-inflammatory lipid mediators (cannabidiol, oleoylethanolamide, stearoylethanolamide, N-arachidonoylethanolamide, and resolvin E1) against PEA on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1494Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • SkQ1

    Plain-language summaryIntrigue 67 / 100

    SkQ1 (Visomitin) is the Russian answer to MitoQ: a mitochondria-targeted antioxidant that uses a positively charged triphenylphosphonium tail to drag plastoquinone, an antioxidant from plant chloroplasts, deep into the mitochondrial inner membrane where oxidative damage actually happens. The molecule was developed by Vladimir Skulachev, one of the giants of mitochondrial bioenergetics, and his group has produced extensive preclinical data in aging models. It is approved as eye drops in Russia for dry eye disease, with measurable clinical benefit. The lifespan and longevity data come almost entirely from Skulachev’s lab, which is the principal weakness of the file. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Mitochondria-targeted plastoquinone-based antioxidant conjugated to a penetrating lipophilic cation (triphenylphosphonium)

    A rechargeable, mitochondria-accumulating plastoquinone derivative developed at Lomonosov Moscow State University as a direct scavenger of reactive oxygen species at the inner mitochondrial membrane, with preclinical geroprotective, cytoprotective, and anti-inflammatory activity across multiple organ systems and a registered ophthalmic formulation (Visomitin) for dry eye syndrome.

    Abstract

    SkQ1 (10-(6′-plastoquinonyl)decyltriphenylphosphonium), designated a “Skulachev ion” after its principal developer Vladimir P. Skulachev, is a synthetic mitochondria-targeted antioxidant composed of a plastoquinone moiety linked by a ten-carbon aliphatic chain to a triphenylphosphonium cation. The triphenylphosphonium group exploits the large negative-inside mitochondrial membrane potential (approximately 180 millivolts) to drive electrophoretic accumulation of the compound within the mitochondrial matrix at concentrations estimated to reach 10(8)-fold above extracellular levels. Within the inner mitochondrial membrane, the plastoquinone headgroup intercalates near the cardiolipin fatty acid chains and directly quenches peroxyl radicals, with regeneration of the reduced (antioxidant-active) form by Complex I at the IQ site and by Complex III at the Qi site of the electron transport chain. This rechargeable antioxidant cycle distinguishes SkQ1 from stoichiometric scavengers and positions it as a catalytic antioxidant with sustained activity at nanomolar external concentrations. The compound was developed beginning in the early 2000s at the A. N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, within a research framework centered on Skulachev’s hypothesis that aging represents a form of programmed organismal death (phenoptosis) mediated by mitochondrial reactive oxygen species (mtROS). Preclinical studies in organisms spanning fungi (Podospora anserina), crustaceans (Ceriodaphnia affinis), insects (Drosophila melanogaster), fish (Nothobranchius furzeri), and mammals (mice and rats) have demonstrated lifespan extension, delay or reversal of age-related pathologies, and suppression of mtROS-driven tissue damage under a variety of experimental conditions. In the senescence-accelerated OXYS rat strain, SkQ1 prevented or reversed cataracts, retinopathy resembling age-related macular degeneration, osteoporosis, and neurodegenerative phenotypes resembling Alzheimer’s disease. In outbred and inbred mouse strains, SkQ1 extended median and maximum lifespan under non-specific-pathogen-free housing conditions, with effect sizes dependent on ambient pathogen exposure. The compound prevented rapid death caused by mechanistically diverse acute shocks including bacterial lipopolysaccharide, intravenous mitochondrial injection, cold exposure, and toxic insult. The ophthalmic formulation of SkQ1 (Visomitin, 0.155 micrograms per milliliter ophthalmic solution) was approved by the Russian Ministry of Health in December 2011 for the treatment of dry eye syndrome and early cataracts. In the United States, Mitotech S.A. advanced SkQ1 ophthalmic solution through a positive Phase 2 clinical trial demonstrating statistically significant improvement in corneal fluorescein staining and lissamine green staining relative to placebo in 91 subjects with mild to moderate dry eye disease. Two subsequent Phase 3 studies (VISTA-1, 452 subjects; VISTA-2, 610 subjects) did not meet their co-primary endpoints, although VISTA-2 demonstrated statistically significant superiority in a pre-specified secondary endpoint of central corneal fluorescein staining change in a Schirmer’s score-defined subpopulation. Phase 1 oral formulation studies were conducted in Russia in 2016. Preclinical pharmacology extends beyond ophthalmology to include cardioprotection (hemorrhagic shock, doxorubicin-induced cardiomyopathy), nephroprotection (cisplatin-induced and ischemia-reperfusion acute kidney injury with ferroptosis inhibition), neuroprotection (stroke, Alzheimer’s disease models in OXYS rats), hepatoprotection, suppression of experimental colitis and autoimmune arthritis, wound healing acceleration, tumor growth inhibition in fibrosarcoma and rhabdomyosarcoma models, and antibacterial activity at micromolar concentrations. Safety pharmacology in rats and dogs has demonstrated a wide therapeutic window with no adverse effects on the central nervous system, cardiovascular system, or respiratory system at doses orders of magnitude above the efficacious range. The compound does not induce hepatic cytochrome P450 enzymes. This monograph reviews the chemistry, structural pharmacology, and rechargeable antioxidant mechanism of SkQ1; the comprehensive preclinical evidence across geroprotective, cytoprotective, and anti-inflammatory applications; the clinical evidence base in dry eye disease; the pharmacokinetic characteristics; sourcing and quality considerations; reconstitution and handling protocols; stack-interaction implications; the adverse-event and safety profile; and a structured comparative assessment of five mitochondria-targeted antioxidant candidates against SkQ1 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1467Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Fluvoxamine

    Plain-language summaryIntrigue 71 / 100

    Fluvoxamine (Luvox) is an SSRI with a structural backbone unlike the others in its class, developed by Solvay and approved in the US in 1994. It is a first-line drug for OCD and also useful in social anxiety. The pharmacological wrinkle that makes researchers care about it is high-affinity activation of the sigma-1 receptor, an unusual cellular target involved in stress response, neuroprotection, and possibly viral defense. That sigma-1 hook briefly made fluvoxamine a topic of pandemic-era research after small trials suggested it might reduce hospitalization risk in early COVID-19, although larger follow-up trials have been mixed. It also strongly blocks the liver enzyme CYP1A2, which raises blood levels of caffeine, theophylline, and several other common drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Selective serotonin reuptake inhibitor with high-affinity sigma-1 receptor agonism

    A 2-aminoethyl oxime ether SSRI developed at Kali-Duphar as an antidepressant and anti-obsessional agent, distinguished from other serotonin reuptake inhibitors by potent sigma-1 receptor agonism and downstream anti-inflammatory, cytoprotective, and endoplasmic reticulum chaperone activity.

    Abstract

    Fluvoxamine, the (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime, is a selective serotonin reuptake inhibitor (SSRI) of the 2-aminoethyl oxime ether structural class, first introduced in Switzerland in 1983 as Floxyfral and approved by the United States Food and Drug Administration in December 1994 for the treatment of obsessive-compulsive disorder (OCD). It is marketed in approximately 80 countries under the trade names Luvox, Fevarin, Faverin, Floxyfral, and Dumyrox for indications including OCD, social anxiety disorder (SAD), and major depressive disorder (MDD), with the extended-release formulation (Luvox CR) approved in the United States in 2008 for both OCD and SAD. Fluvoxamine is pharmacologically distinguished from the other marketed SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) by its potent agonism at the sigma-1 receptor, a ligand-regulated endoplasmic reticulum chaperone protein, with a binding affinity (Ki approximately 36 nM) that is the highest of any clinically used SSRI and approximately 10-fold greater than that of sertraline, the next most potent sigma-1 ligand in the class [1, 2]. The sigma-1 receptor activity, formally characterized by Narita et al. (1996) and subsequently extended by multiple laboratory groups in rodent models and by Hashimoto and colleagues in translational studies, drives a pharmacological profile that extends substantially beyond serotonin reuptake inhibition: activation of the sigma-1 receptor chaperone at the mitochondria-associated endoplasmic reticulum membrane (MAM) modulates the inositol 1,4,5-trisphosphate receptor (IP3R), stabilizes the IRE1-BiP complex under endoplasmic reticulum stress, suppresses NLRP3 inflammasome and NF-kappaB-driven proinflammatory cytokine release, and potentiates nerve growth factor-induced neurite outgrowth in neuronal cell models [3, 4, 5]. These properties have positioned fluvoxamine as a candidate for drug repositioning in inflammatory and infectious disease, most notably in the SARS-CoV-2 pandemic, where the TOGETHER trial (Reis et al. 2022) demonstrated a 32 percent relative risk reduction in the composite endpoint of emergency department retention or hospitalization among high-risk COVID-19 outpatients treated with fluvoxamine 100 mg twice daily for 10 days compared to placebo [6]. Pharmacokinetics in humans are characterized by near-complete gastrointestinal absorption, approximately 53 percent oral bioavailability due to first-pass hepatic metabolism, a plasma elimination half-life of 12 to 15 hours after single doses (extended at steady state owing to nonlinear pharmacokinetics from autoinhibition of CYP1A2 and CYP2C19), and oxidative demethylation through CYP2D6 and CYP1A2 followed by glucuronide conjugation and renal excretion [7, 8]. Fluvoxamine is itself a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP3A4 and CYP2C9, producing clinically significant drug-drug interactions with theophylline, tizanidine, alosetron, clozapine, warfarin, and ramelteon, among others [9]. The compound is well tolerated at registered doses; the principal adverse events are nausea (up to 40 percent), somnolence, insomnia, headache, and asthenia, with serotonin syndrome as a rare but serious risk in combination with other serotonergic agents or monoamine oxidase inhibitors. This monograph reviews the chemistry, synthesis, and structural class of fluvoxamine; the dual SSRI and sigma-1 receptor pharmacology in molecular and translational detail; the comprehensive human pharmacokinetic record; the clinical evidence base across OCD, SAD, MDD, COVID-19, and investigational anti-inflammatory indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five serotonergic or sigma-1-active compounds against fluvoxamine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1465Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Acarbose

    Plain-language summaryIntrigue 70 / 100

    Acarbose (Precose) is an alpha-glucosidase inhibitor isolated from a soil bacterium and approved in 1996 for type 2 diabetes. It blocks intestinal enzymes that break down complex carbohydrates, slowing carbohydrate absorption and flattening post-meal glucose spikes. Clinically it is a second-tier diabetes drug owing to gastrointestinal side effects (gas, bloating) from undigested carbohydrate fermenting in the colon. The longevity interest comes from the NIA Interventions Testing Program, which reproducibly showed that acarbose extends mouse lifespan, particularly in males, with effects that hold across different diets and genetic backgrounds. The replication is unusually solid for a longevity compound, even if the mouse-to-human translation is uncertain. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Pseudotetrasaccharide alpha-glucosidase inhibitor with pancreatic alpha-amylase inhibitory activity

    A microbially derived pseudotetrasaccharide developed at Bayer AG as a competitive intestinal alpha-glucosidase and pancreatic alpha-amylase inhibitor for postprandial glucose control in type 2 diabetes mellitus, with emerging preclinical evidence for lifespan extension, gut microbiome modulation, and cardiovascular risk reduction.

    Abstract

    Acarbose is a pseudotetrasaccharide alpha-glucosidase inhibitor isolated from fermentation cultures of the actinobacterium Actinoplanes utahensis and subsequently produced at industrial scale by Actinoplanes sp. SE50/110. The compound competitively and reversibly inhibits the brush border alpha-glucosidases (maltase-glucoamylase, sucrase-isomaltase) of the small intestinal epithelium and, at higher concentrations, pancreatic alpha-amylase, thereby delaying the hydrolysis of complex carbohydrates and oligosaccharides to absorbable monosaccharides and producing a dose-dependent reduction in postprandial glycemic excursion without direct stimulation of insulin secretion [1, 2]. Acarbose received its first regulatory approval in Germany in 1990 and was approved by the United States Food and Drug Administration in 1995 under the trade name Precose; it is marketed in over 100 countries worldwide as Glucobay (Bayer) and under multiple generic names. The compound is one of the most widely prescribed antidiabetic agents in East Asia, where postprandial hyperglycemia contributes disproportionately to overall glycemic burden in carbohydrate-rich dietary patterns. The pharmacokinetic profile of acarbose is dominated by its topical mechanism of action within the gastrointestinal lumen. Less than 2 percent of an oral dose is absorbed as intact drug; the remainder is degraded by intestinal bacteria and digestive enzymes in the distal small intestine and colon, producing at least 13 metabolites, of which one (4-methylpyrogallol and its conjugates) accounts for the majority of systemically absorbed radioactivity [3, 4]. Systemic exposure is therefore minimal, and the pharmacodynamic effect is determined by intraluminal drug concentration relative to the enzyme targets rather than by plasma pharmacokinetics. The compound is not metabolized by hepatic cytochrome P450 enzymes and has negligible renal clearance of intact drug. Clinical evidence for acarbose in type 2 diabetes mellitus is extensive. Pivotal registration trials demonstrated reductions in glycated hemoglobin (HbA1c) of 0.5 to 0.8 percentage points and reductions in postprandial glucose of 40 to 60 mg/dL at oral doses of 50 to 100 mg three times daily with meals [5, 6]. The UKPDS 44 substudy confirmed sustained glycemic efficacy over 3 years as add-on therapy to sulfonylurea or metformin [7]. The STOP-NIDDM trial (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) in 1368 subjects with impaired glucose tolerance demonstrated a 25 percent relative risk reduction in progression to type 2 diabetes and a 49 percent relative risk reduction in cardiovascular events over 3.3 years of treatment, though the cardiovascular endpoint was secondary and based on a small number of events [8, 9]. The larger ACE trial (Acarbose Cardiovascular Evaluation) in 6522 Chinese patients with coronary heart disease and impaired glucose tolerance found no reduction in major adverse cardiovascular events over 5 years of follow-up but confirmed an 18 percent relative risk reduction in incident diabetes [10]. Beyond the established antidiabetic indication, acarbose has attracted substantial recent interest as a longevity intervention. The National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse study, demonstrated that acarbose at 1000 ppm in chow extended median lifespan by approximately 22 percent in males and 5 percent in females, with corresponding increases in maximum lifespan [11, 12]. The sex-differential effect parallels the male-preferential lifespan extension observed with 17-alpha-estradiol and nordihydroguaiaretic acid in the same program. Mechanistic investigations have linked the longevity effect to increased delivery of undigested starch to the colonic microbiome, resulting in elevated production of short-chain fatty acids (butyrate, propionate, acetate), shifts in microbial community composition toward Bacteroidetes-dominant profiles, and reductions in circulating insulin-like growth factor 1 (IGF-1) and fasting insulin [13, 14]. Combination of acarbose with rapamycin in the ITP produced additive lifespan extension (median lifespan increases of 28 percent in females and 34 percent in males when initiated at 9 months of age), supporting the hypothesis that the two compounds operate through complementary pathways [15]. The principal adverse effects of acarbose are gastrointestinal: flatulence (reported in up to 78 percent of patients at initiation), diarrhea, and abdominal discomfort, all reflecting the mechanism of action (bacterial fermentation of undigested carbohydrate in the colon) and typically diminishing with continued therapy and gradual dose titration [16]. Rare hepatotoxicity, presenting as asymptomatic transaminase elevation or, in isolated cases, clinically apparent hepatocellular injury, has been reported in postmarketing surveillance and is generally reversible upon discontinuation [17]. This monograph reviews the chemistry, biosynthesis, and structural pharmacology of acarbose; the mechanism of alpha-glucosidase and alpha-amylase inhibition at the molecular level; the comprehensive pharmacokinetic record; the clinical evidence base across antidiabetic, diabetes prevention, cardiovascular, and longevity indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative glucose-lowering or longevity-relevant compounds against acarbose on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1476Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • CP2

    Tricyclic pyrone mild mitochondrial complex I inhibitor with direct amyloid-beta binding activity

    A cell-permeable tricyclic pyranopyrone synthesized at Kansas State University as an anti-amyloidogenic agent, subsequently characterized as a mild inhibitor of mitochondrial complex I that activates AMPK-dependent neuroprotective signaling, crosses the blood-brain barrier, and reduces amyloid-beta, phosphorylated tau, oxidative stress, and neuroinflammation in multiple transgenic mouse models of familial Alzheimer’s disease.

    Abstract

    CP2 is a synthetic tricyclic pyrone (pyranopyrone) small molecule originally developed as part of a structure-activity exploration of anti-amyloidogenic agents in the laboratory of Duy H. Hua at Kansas State University and first reported in the biomedical literature as a cell-permeable inhibitor of amyloid-beta oligomeric complex formation in the MC65 neuroblastoma conditional expression system by Maezawa et al. (2006) [1]. The compound consists of a fused tricyclic pyranopyrone skeleton bearing an adenine moiety attached through its N3′ nitrogen to the C7 isopropyl substituent of the cyclohexane ring. CP2 exists as two diastereomers, designated D1 and D2, with distinct pharmacological activity and toxicity profiles that have been resolved by X-ray crystallography and cryo-electron microscopy at 3.25 to 3.27 angstrom resolution [2]. The D1 diastereomer is the more pharmacologically active form. The compound was initially characterized as a direct binder of amyloid-beta peptides, with exceptionally high binding affinity to amyloid-beta 40 (Kd approximately 5.05 nanomolar) and high affinity to amyloid-beta 42 (Kd approximately 269 nanomolar), and as an inhibitor of amyloid-beta oligomerization and fibril formation in surface plasmon resonance and atomic force microscopy assays [3, 4]. Subsequent mechanistic investigation by Zhang et al. (2015) identified the primary intracellular target as mitochondrial complex I (NADH:ubiquinone oxidoreductase), the first and largest enzyme complex of the electron transport chain [5]. Molecular dynamics simulations and cryo-electron microscopy demonstrated that the cationic CP2 molecule competes with flavin mononucleotide for binding to the redox subunit of human mitochondrial complex I, leading to mild (partial) inhibition of complex I activity, elevated AMP-to-ATP ratio, and consequent activation of AMP-activated protein kinase (AMPK) in neurons and in mouse brain without inducing oxidative damage or inflammation [5, 6]. In vivo, CP2 is orally bioavailable, penetrates the blood-brain barrier, and accumulates in neuronal mitochondria. Chronic oral administration at 25 mg/kg/day in drinking water in multiple transgenic mouse models of familial Alzheimer’s disease (Tg2576, 3xTg-AD, APP/PS1, 5xFAD) has produced consistent reductions in amyloid-beta and phosphorylated tau accumulation, oxidative stress, neuroinflammation, and cognitive dysfunction, while improving mitochondrial function, energy homeostasis, synaptic activity, dendritic spine density and morphology, and long-term potentiation in the hippocampus [5, 7, 8, 9]. The compound also prevents aggregation and reverses cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons, extending the potential disease relevance beyond Alzheimer’s disease to Huntington’s disease [10]. A 2025 study by Gao et al. demonstrated that mitochondrial complex I deficiency alone induces Alzheimer’s disease-like transcriptomic signatures in the brain, and that these signatures are partially reversible by CP2 treatment, providing further mechanistic support for the therapeutic strategy [11]. CP2 has not entered human clinical trials. The compound remains a preclinical research tool and investigational candidate. Structure-activity relationship studies have produced a next-generation analog, C458 (cis-(N-(pyridin-4-ylmethyl)-2-(3-(m-tolyloxy)cyclohexyl)propan-1-amine)), with improved drug-like properties, favorable pharmacokinetics, minimal off-target effects, and excellent brain penetrance [2, 12]. This monograph reviews the chemistry, synthesis, and stereochemistry of CP2; the dual mechanism of action encompassing direct amyloid-beta binding and mild mitochondrial complex I inhibition; the pharmacokinetic profile in rodents; the preclinical evidence base across Alzheimer’s disease and Huntington’s disease models; sourcing and handling considerations for laboratory use; stack interaction considerations; the adverse event and safety signal from preclinical data; and a comparative assessment of five mitochondrial-targeted or anti-amyloidogenic neuroprotective candidates against CP2 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory agency and is not registered as a medicine in any jurisdiction. It is supplied as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1471Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.